HeartSciences Inc. (NASDAQ:HSCS) Short Interest Update

HeartSciences Inc. (NASDAQ:HSCS) saw a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 50,682 shares, a drop of 33.3% from the July 30th total of 76,030 shares. Currently, 1.4% of the shares of the company are short sold. Based on an average daily volume of 66,843 shares, the days-to-cover ratio is presently 0.8 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, HeartSciences presently has an average rating of “Hold” and a consensus target price of $8.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in HeartSciences stock. Geode Capital Management LLC bought a new stake in HeartSciences Inc. (NASDAQ:HSCS) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.51% of HeartSciences as of its most recent filing with the Securities & Exchange Commission. 17.24% of the stock is owned by institutional investors.

HeartSciences Trading Down 3.5%

HSCS stock opened at $3.01 on Thursday. The company has a market capitalization of $11.74 million, a P/E ratio of -0.76 and a beta of 1.84. The business has a 50 day simple moving average of $2.55 and a 200-day simple moving average of $2.35. HeartSciences has a twelve month low of $1.63 and a twelve month high of $3.80.

HeartSciences (NASDAQ:HSCS) last announced its earnings results on Thursday, July 23rd. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.22). Research analysts predict that HeartSciences will post -3.04 EPS for the current fiscal year.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.